At Ethicon we are working with thought-leading surgeons, researchers and endocrinologists to understand the physiological changes that can occur after bariatric surgery in order to develop new, beneficial therapies for the many patients who suffer from obesity and metabolic diseases such as type 2 diabetes.
Our approach is to deconstruct the current weight loss procedures, understand what makes bariatric surgery effective and use this understanding to invent new less invasive, less expensive solutions that deliver better, long term outcomes for patients.
By understanding how existing bariatric surgical procedures work, our team can use this information to develop more effective technology, including:
- Surgical techniques
- Devices
- Drugs
- Nutritional agents
We believe that developing new, less invasive therapies will help more people win their battle against obesity and other metabolic diseases.
To learn about Ethicon's latest research project, MARS, please visit the Metabolic Applied Research Strategy page.
Obesity is a global challenge
It is evident that obesity is a major worldwide health issue which has become an epidemic over the last decades, posing one of the greatest public health challenges of the 21st Century. Obesity affects not only adults, but also children and adolescents.
Obesity is linked to a variety of health problems such as type 2 diabetes, joint pain and ischemic heart disease. In addition to human suffering, the burden on national health costs alone shows that the economic implications are substantial.
Bariatric surgery is the only treatment option that has been able to produce clinical evidence of long-term, positive effects on weight loss and associated metabolic diseases such as type 2 diabetes. We are committed to developing the next generation of innovative surgical techniques and products that will improve both surgical outcomes and efficiency.
Ethicon Announcements
Ethicon is investing heavily in both internal and external Research & Development initiatives, further improving the understanding of obesity in terms of condition progression, associated metabolic diseases, and the impact of surgical intervention.
Ethicon, in collaboration with other Johnson & Johnson cooperative companies, has the capacity for and is committed to developing new interventional therapies for obesity and metabolic diseases, especially type 2 diabetes, by bringing together the resources and expertise of the device, nutritional and pharmaceutical cooperative companies within Johnson & Johnson.
Ethicon is the only company that supports all three of the primary bariatric and metabolic surgeries - gastric bypass, sleeve gastrectomy and gastric banding - through its products, research and educational efforts.
